Clinical trials: Tick-borne Encephalitis
Tick-Borne Encephalitis, Encephalitis, Tick-Borne
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
This was an open label trial of a non-US licensed vaccine for tick-borne encephalitis. The vaccine was licensed by Baxter, and now following an acquisition by Pfizer Inc in Vienna, Austria since 2001, and has an extensive safety…
- Conditions
- Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus
- Trial name
- TBEV (NCT01031537)
- Testing
- FSME-IMMUN 0.5ml Baxter
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Encephalitis, Tick-Borne
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or…
- Trial name
- NCT00840801
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis, Virus Diseases
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so…
- Trial name
- NCT01562444
- Testing
- Blood draw
- Where
- Czechia
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick Borne Encephalitis
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Patients undergoing allogeneic blood and marrow transplantation (HSCT) experience a prolonged period of dysfunctional immunity. Systematic reimmunization is necessary at appropriate time intervals following transplantation to…
- Trial name
- NCT01991067
- Testing
- TBE virus vaccine
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Virus Diseases
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine.
- Trial name
- NCT03294135
- Testing
- Encepur Adults
- Where
- Czechia
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Responsiveness in Allergy, Vaccine Responsiveness During Allergy De-sensitization Treatment
TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Allergic patients especially those undergoing de-sensitization treatment have an altered immune responsiveness. The investigators aim to find out whether this influences immune responses to primary and booster vaccinations.
- Trial name
- NCT02511535
- Testing
- TBE booster vaccination
- Where
- Austria
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna